← Back to Home

Tumor shrinkage fails to deliver primary endpoint success: Phase 3 lung cancer setback for firmonertinib sends ArriVent shares down nearly 47%

Although the high-dose group had a higher tumor response rate, independent review did not show a significant delay in disease progression. The result is a setback for treatment hopes in lung cancer with a rare EGFR mutation and adds uncertainty to the global development of this drug licensed from China.

By SURL BioNews

Tumor shrinkage is an important signal in cancer treatment, but whether that response translates into longer disease control remains a question for clinical trials. ArriVent announced on October 6 that its oral targeted drug firmonertinib failed to meet the primary endpoint of progression-free survival in the Phase 3 FURVENT trial. The South China Morning Post reported that the company's shares closed down nearly 47% that day, reflecting market disappointment with this pivotal result.

FURVENT enrolled 398 patients with nonsquamous non-small cell lung cancer harboring EGFR exon 20 insertion mutations who had not received systemic treatment for advanced disease. The trial compared firmonertinib at daily doses of 240 mg and 160 mg with platinum-based chemotherapy plus pemetrexed. The primary assessment used blinded independent central review to evaluate the time from treatment initiation to disease progression or death.

According to the company's announcement and a summary by OncLive, median progression-free survival was 11.0 months in the 240 mg group and 9.5 months in the chemotherapy group. The hazard ratio was 0.75, but the 95% confidence interval was 0.55 to 1.02 and the P value was 0.0654, falling short of statistical significance. Median progression-free survival in the 160 mg group was 8.4 months. The numerically better result in the high-dose group was still insufficient for the trial to declare success on its primary endpoint.

Other efficacy measures presented a more complex picture. The independently confirmed objective response rate—the proportion of patients whose tumor shrinkage met specified criteria—was 60%, 35%, and 33% in the 240 mg, 160 mg, and chemotherapy groups, respectively. Investigator-assessed progression-free survival also favored the high-dose group. However, these results cannot replace the prespecified primary analysis. Overall survival data remain immature, and the favorable trend cited by the company cannot yet be considered evidence of longer survival.

On safety, the rates of grade 3 or higher treatment-related adverse events in the three groups were 26%, 22%, and 40%, respectively. When adverse events that emerged during treatment but were not necessarily causally related to the drug were counted, the corresponding rates were 52%, 53%, and 55%. The company said no new safety signals were identified, but lower treatment-related toxicity still needs to be weighed alongside disease control.

This setback also affects the development outlook for a drug licensed across borders. According to the South China Morning Post, firmonertinib was originally developed by Shanghai Allist, while ArriVent is advancing its international development. FURVENT shows that even when a drug has demonstrated clinical activity, it must still establish benefit in a specific patient population against a comparator treatment in a global randomized trial. ArriVent said it is evaluating the full data to determine the subsequent development path. The result cannot yet be interpreted as the termination of the entire drug program.

Background

The performance of the same EGFR inhibitor cannot be directly extrapolated from one mutation population to another. The setback occurred in a first-line treatment trial for lung cancer with exon 20 insertion mutations, while another Phase 3 trial, ALPACCA, targets EGFR PACC mutations. Although both trials use the same drug, they address different clinical questions. The FURVENT result increases development risk, but it does not establish a conclusion about efficacy in the PACC population.

References

  1. The Business Journals
  2. OncLive
  3. South China Morning Post